Ronnie Speight - Syneos Health Vice President Investor Relations
| SYNHDelisted Stock | USD 42.31 0.07 0.17% |
President
Ronnie Speight is Vice President Investor Relations of Syneos Health since 2016.
| Tenure | 8 years |
| Phone | 919 876 9300 |
| Web | https://www.syneoshealth.com |
Syneos Health Management Efficiency
The company has return on total asset (ROA) of 0.0263 % which means that it generated a profit of $0.0263 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0209 %, meaning that it created $0.0209 on every $100 dollars invested by stockholders. Syneos Health's management efficiency ratios could be used to measure how well Syneos Health manages its routine affairs as well as how well it operates its assets and liabilities.Syneos Health currently holds 2.9 B in liabilities with Debt to Equity (D/E) ratio of 0.93, which is about average as compared to similar companies. Syneos Health has a current ratio of 1.08, suggesting that it may have difficulties to pay its financial obligations when due. Note, when we think about Syneos Health's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Eric Sherbet | IQVIA Holdings | 60 | |
| Michael Knell | Charles River Laboratories | 47 | |
| Riaz MBA | Sotera Health Co | 54 | |
| Thomas Schweins | Qiagen NV | N/A | |
| Mital Patel | RadNet Inc | 38 | |
| Kevin Knightly | IQVIA Holdings | 63 | |
| Joseph Shrawder | Sotera Health Co | N/A | |
| Michael McDonnell | IQVIA Holdings | 55 | |
| Rob Kotchie | IQVIA Holdings | N/A | |
| Simon Holmes | ICON PLC | 57 | |
| Wendy Stewart | IQVIA Holdings | N/A | |
| Ronald Bruehlman | IQVIA Holdings | 63 | |
| William Barbo | Charles River Laboratories | 63 | |
| Brian Caveney | Laboratory of | 47 | |
| Sandra Vaart | Laboratory of | 64 | |
| Joseph LaPlume | Charles River Laboratories | 50 | |
| Brian Mi | IQVIA Holdings | 58 | |
| Walter Staub | IQVIA Holdings | 57 | |
| Birgit Girshick | Charles River Laboratories | 54 | |
| Nilton Paletta | IQVIA Holdings | N/A | |
| Steven PharmD | Aclaris Therapeutics | N/A | |
Management Performance
| Return On Equity | 0.0209 | |||
| Return On Asset | 0.0263 |
Syneos Health Leadership Team
Elected by the shareholders, the Syneos Health's board of directors comprises two types of representatives: Syneos Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Syneos. The board's role is to monitor Syneos Health's management team and ensure that shareholders' interests are well served. Syneos Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Syneos Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jason Meggs, Interim CFO, Executive Vice President | ||
| Jonathan Olefson, General Counsel, Corporate Secretary | ||
| Michael Brooks, Chief Officer | ||
| Judith MD, Chief Officer | ||
| Alistair Macdonald, CEO, Director | ||
| Ronnie Speight, Vice President Investor Relations | ||
| Baba Shetty, Pres Solutions | ||
| Michelle Keefe, CEO Director | ||
| Larry Pickett, Chief Officer | ||
| Donna Kralowetz, Sr Officer |
Syneos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Syneos Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0209 | |||
| Return On Asset | 0.0263 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 7.23 B | |||
| Shares Outstanding | 103.72 M | |||
| Shares Owned By Insiders | 0.48 % | |||
| Shares Owned By Institutions | 94.74 % | |||
| Number Of Shares Shorted | 6.76 M | |||
| Price To Earning | 18.05 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Syneos Stock
If you are still planning to invest in Syneos Health check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Syneos Health's history and understand the potential risks before investing.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |